Startup profile · funding coverage
NewLimit funding, valuation and investors
Therapeutics developer pursuing epigenetic reprogramming of aged cells.
Verified company research · funding, investors and latest developments
Keep track of NewLimit
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series C
$435M · June 2, 2026
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$435M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
growth · United States
Investors in latest funding
Lead: Founders Fund
Other: Thrive Capital , Greenoaks , Quiet Capital
Overview
NewLimit is developing medicines intended to restore function in aged cells using epigenetic reprogramming approaches. Its June 2, 2026 financing announcement disclosed a $435 million Series C led by Founders Fund, with participation from Thrive Capital, Greenoaks, Quiet Capital and returning investors. The company has discussed plans to advance a prototype therapy toward human trials in 2027.
This is a company plan, not evidence a trial has already succeeded. Source: https://blog.newlimit.com/p/newlimit-raises-435m-led-by-founders
Why NewLimit is interesting
NewLimit's $435M June 2026 Series C backs a high-risk approach to aging-related disease; the next differentiator is whether reported cell reprogramming findings translate into human safety and efficacy.
Product & use cases
Research in cell reprogramming and therapeutic approaches to aging-associated disease.
Funding history (newest first)
Series C
2026-06-02 $435M- Founders Fund (lead)
- Thrive Capital (participant)
- Greenoaks (participant)
- Quiet Capital (participant)
Source: Read source · blog.newlimit.com
Competitive landscape
Edge: A focused reprogramming platform and significant capital to fund translational research.
The theoretical market for aging-related disease is large but commercial positioning cannot be inferred from cell-level results. Clinical trial safety, effective delivery, selected indication and intellectual property remain key risks.
Industries
Market / IPO context
Editorial / static context — not a live quote.
FAQs about NewLimit
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.